This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Iratumumab" – news · newspapers · books · scholar · JSTOR(August 2012) (Learn how and when to remove this message)
Iratumumab
Monoclonal antibody
Type
Whole antibody
Source
Human
Target
CD30
Clinical data
ATC code
none
Identifiers
CAS Number
640735-09-7N
ChemSpider
none
UNII
AYH22O1B1U
KEGG
D04612Y
Chemical and physical data
Formula
C6358H9830N1682O1992S38
Molar mass
142922.64 g·mol−1
NY (what is this?)(verify)
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.[1]
This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb.
The FDA granted orphan drug designation for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given.[2]
^Statement On A Nonproprietary Name Adopted By The USAN Council – Iratumumab, American Medical Association.
^"Iratumumab". AdisInsight. Retrieved 30 January 2017.
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's...
Global Information
(what is this?) (verify)